Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jan, 2015 | Pages:
50 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Peripheral neuropathy is the nerve damaged that is caused by diabetes and constant high blood sugar. This results in to loss of sensation, numbness, and pain in your hands, fetes and legs. The disease is considered to be the most common complication of diabetes. In addition, more or less 60% to 70% of all people will ultimately develop peripheral neuropathy but not all go through pain. The overall cost of curing foot ulcers and DPN are projected assuming that occurrence rates remain the same throughout a year. In addition, Regular prevalence does not need at the same patients stay in that health state. Diabetic peripheral neuropathy (DPN) develops slowly and worsens over time as the condition does not emerge overnight. Also, they people suffering have condition long before they are diagnosed with diabetes. Patient suffering with diabetes for many years may augment the tendency of getting diagnosed with diabetic neuropathy. Although, there are few methods and research designs for diabetic peripheral neuropathy are recognized in the worldwide market. One of the key methods implemented in the U.S is a cost-of-illness model which was used to calculate several numbers of diabetic individuals who are suffering from diabetic peripheral neuropathy in the region. Incidence rates and prevalence were estimated from published studies and applied to the general U.S Population. Although, total cost was valued in 2001 U.S dollars. This is likely to impact the overall diabetic peripheral neuropathy market. According to the report, major market players are working on new techniques, methods and approaches to demonstrate new treatment techniques, Key regions operating in the diabetic peripheral neuropathy market are Asia Pacific, Europe and the U.S .Around 3.2% of the people in the US are suffering from diabetes and are estimated that over 50% have some degree of peripheral neuropath. In the region, the total annual cost of curing DPN and its complications was around $10 billion. The overall cost of curing foot ulcers and DPN are projected assuming that occurrence rates remain the same throughout a year. In addition, Regular prevalence does not need at the same patients stay in that health state
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Diabetic Peripheral Neuropathy Overview 6 Therapeutics Development 7 Pipeline Products for Diabetic Peripheral Neuropathy - Overview 7 Pipeline Products for Diabetic Peripheral Neuropathy - Comparative Analysis 8 Diabetic Peripheral Neuropathy - Therapeutics under Development by Companies 9 Diabetic Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 10 Diabetic Peripheral Neuropathy - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Diabetic Peripheral Neuropathy - Products under Development by Companies 13 Diabetic Peripheral Neuropathy - Products under Investigation by Universities/Institutes 14 Diabetic Peripheral Neuropathy - Companies Involved in Therapeutics Development 15 Astellas Pharma Inc. 15 BioChemics, Inc. 16 Cebix Incorporated 17 Pfizer Inc. 18 ViroMed Co., Ltd. 19 Diabetic Peripheral Neuropathy - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Target 21 Assessment by Mechanism of Action 23 Assessment by Route of Administration 25 Assessment by Molecule Type 27 Drug Profiles 29 Antimunocel - Drug Profile 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 ASP-8477 - Drug Profile 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 benfotiamine - Drug Profile 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 CBX-129801 - Drug Profile 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 CNV-2197944 - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 epalrestat - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 PF-05089771 - Drug Profile 38 Product Description 38 Mechanism of Action 38 R&D Progress 38 Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 40 Product Description 40 Mechanism of Action 40 R&D Progress 40 VM-202 - Drug Profile 41 Product Description 41 Mechanism of Action 41 R&D Progress 41 Diabetic Peripheral Neuropathy - Recent Pipeline Updates 43 Diabetic Peripheral Neuropathy - Dormant Projects 46 Diabetic Peripheral Neuropathy - Discontinued Products 47 Diabetic Peripheral Neuropathy - Product Development Milestones 48 Featured News & Press Releases 48 Jun 09, 2012: Cebix's Ersatta Demonstrates Encouraging Results In Phase I Study Of Diabetic Peripheral Neuropathy 48 Appendix 49 Methodology 49 Coverage 49 Secondary Research 49 Primary Research 49 Expert Panel Validation 49 Contact Us 50 Disclaimer 50
List of Tables Number of Products under Development for Diabetic Peripheral Neuropathy, H1 2015 7 Number of Products under Development for Diabetic Peripheral Neuropathy - Comparative Analysis, H1 2015 8 Number of Products under Development by Companies, H1 2015 9 Number of Products under Investigation by Universities/Institutes, H1 2015 10 Comparative Analysis by Clinical Stage Development, H1 2015 11 Comparative Analysis by Early Stage Development, H1 2015 12 Products under Development by Companies, H1 2015 13 Products under Investigation by Universities/Institutes, H1 2015 14 Diabetic Peripheral Neuropathy - Pipeline by Astellas Pharma Inc., H1 2015 15 Diabetic Peripheral Neuropathy - Pipeline by BioChemics, Inc., H1 2015 16 Diabetic Peripheral Neuropathy - Pipeline by Cebix Incorporated, H1 2015 17 Diabetic Peripheral Neuropathy - Pipeline by Pfizer Inc., H1 2015 18 Diabetic Peripheral Neuropathy - Pipeline by ViroMed Co., Ltd., H1 2015 19 Assessment by Monotherapy Products, H1 2015 20 Number of Products by Stage and Target, H1 2015 22 Number of Products by Stage and Mechanism of Action, H1 2015 24 Number of Products by Stage and Route of Administration, H1 2015 26 Number of Products by Stage and Molecule Type, H1 2015 28 Diabetic Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H1 2015 43 Diabetic Peripheral Neuropathy - Dormant Projects, H1 2015 46 Diabetic Peripheral Neuropathy - Discontinued Products, H1 2015 47
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
